Abbott Laboratories (ABT) EVP granted options and performance-based stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Moreland Mary K reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories executive vice president Mary K. Moreland reported equity awards on common stock. She received an employee stock option covering 57,512 shares that vests in three annual installments starting February 24, 2027, and a performance-based restricted stock award of 13,951 shares with a three-year term tied to return-on-equity targets.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Moreland Mary K
Role
EXECUTIVE VICE PRESIDENT
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 57,512 | $0.00 | -- |
| Grant/Award | Common shares without par value | 13,951 | $0.00 | -- |
| holding | Common shares without par value | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 57,512 shares (Direct);
Common shares without par value — 109,534 shares (Direct);
Common shares without par value — 11,845 shares (Indirect, Profit Sharing Trust)
Footnotes (1)
- These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,170 on February 24, 2027, 19,171 on February 24, 2028, and 19,171 on February 24, 2029.
FAQ
What did Abbott Laboratories (ABT) executive Mary K. Moreland report on this Form 4?
Mary K. Moreland reported equity awards in Abbott Laboratories stock. She received an option for 57,512 shares and a performance-based restricted stock award of 13,951 shares, both granted under the Abbott Laboratories 2017 Incentive Stock Program on February 24, 2026.
How many Abbott Laboratories options did Mary K. Moreland acquire?
Mary K. Moreland acquired an employee stock option covering 57,512 Abbott Laboratories shares. The option was granted under the 2017 Incentive Stock Program and becomes exercisable in three annual increments beginning on February 24, 2027, then February 24, 2028, and February 24, 2029.
What are the terms of Mary K. Morelands performance-based restricted stock award in ABT?
The performance-based restricted stock award covers 13,951 Abbott Laboratories shares. It has a three-year term, with no more than one-third vesting in any single year, and vesting requires Abbott to reach a minimum return-on-equity target, with shares eligible to be withheld for taxes.
Under which plan were Mary K. Morelands Abbott equity awards granted?
Both the stock option and the performance-based restricted stock award were granted under the Abbott Laboratories 2017 Incentive Stock Program. The option grant is described as exempt from Section 16 under Rule 16b-3, reflecting its status as a compensatory employee award.
How do the vesting increments work for Mary K. Morelands Abbott stock option?
The stock option becomes exercisable in three tranches: 19,170 shares on February 24, 2027, 19,171 shares on February 24, 2028, and 19,171 shares on February 24, 2029. These annual increments structure the exercisability of the full 57,512-share option grant over time.
What indirect Abbott Laboratories holdings were reported for Mary K. Moreland?
An indirect holding balance was reported in the Abbott Laboratories Stock Retirement Trust. The filing notes this balance as of February 24, 2026, and identifies it as a profit-sharing trust position, separate from her directly held common shares and newly granted equity awards.